Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
US-2024336624-A1 · Oct 10, 2024 · US
1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8993591B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993591-B2 |
| Application number | US-201113883818-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 8, 2011 |
| Priority date | Nov 8, 2010 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of formula (I) or a stereochemically isomeric form thereof, wherein R 1 is selected from the group consisting of C 1-6 alkyl, (C 3-8 cycloalkyl)C 1-3 alkyl, (C 1-3 alkyloxy)C 1-3 alkyl, and C 1-3 alkyl substituted with 1, 2 or 3 fluoro substituents; R 2 is selected from the group consisting of Cl, CF 3 , —C…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993591B2 cover?
- The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders a…
- Who is the assignee on this patent?
- Cid-Núñez José Maria, Trabanco-Suárez Andrés Avelino, Vega Ramiro Juan Antonio, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/498. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).